FLG-1: A Potential Drug Target and Biomarker (G2312)
FLG-1: A Potential Drug Target and Biomarker
FLG-1, also known as CD28, is a protein that is expressed in various tissues of the body, including the immune system, and is involved in cell-mediated immune responses. FLG-1 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.
The protein encoded by the FLG-1 gene is a member of the B cell lymphoma 1 (BCL-1) family, which is characterized by the presence of a unique N-terminal transmembrane domain and a central immunoglobulin (Ig) domain. The BCL-1 family is involved in the regulation of cell proliferation, differentiation, and survival, and is implicated in the development and progression of various diseases, including cancer.
FLG-1 has been shown to play a role in the regulation of T cell responses, which are a critical part of the immune system. T cells are responsible for recognizing and responding to foreign antigens, including viruses and cancer cells. During T cell activation , FLG-1 is involved in the formation of the T cell receptor (TCR), which is a critical structure that allows T cells to recognize and respond to antigens.
FLG-1 has also been shown to be involved in the regulation of B cell responses, which are responsible for producing antibodies as part of the immune response. During B cell development, FLG-1 is involved in the regulation of cell proliferation and differentiation, as well as the formation of antibody clones.
In addition to its role in immune system function, FLG-1 has also been implicated in the development and progression of various diseases. For example, FLG-1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, FLG-1 has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.
As a potential drug target, FLG-1 has the potential to be used for the treatment of a variety of diseases. For example, FLG-1 has been shown to be involved in the regulation of T cell responses, which makes it a potential target for drugs that can modulate T cell activity. Additionally, FLG-1 has been shown to be involved in the regulation of B cell responses, which makes it a potential target for drugs that can modulate B cell activity.
In conclusion, FLG-1 is a protein that is involved in cell-mediated immune responses and has been implicated in the development and progression of various diseases. As a potential drug target and biomarker, FLG-1 has the potential to be used for the treatment of a variety of diseases. Further research is needed to fully understand the role of FLG-1 in disease development and the potential utility of FLG-1 as a drug.
Protein Name: Filaggrin
Functions: Aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments during terminal differentiation of mammalian epidermis
More Common Targets
FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4 | FNDC1 | FNDC10 | FNDC11 | FNDC3A | FNDC3B | FNDC4 | FNDC5 | FNDC7 | FNDC8 | FNDC9 | FNIP1 | FNIP2 | FNTA | FNTB | FOCAD | Focal Adhesion Kinases (FAK) | Folate Receptor | FOLH1 | FOLH1B | Follicle stimulating hormone | FOLR1 | FOLR2 | FOLR3 | Formin homology 2 domain-containing proteins | FOS | FOSB | FOSL1 | FOSL2
